Bellerophon Therapeutics (BLPH) Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BLPH shares.
View BLPH analyst ratings or view top-rated stocks.

2 brokers have issued 12-month target prices for Bellerophon Therapeutics' shares. Their BLPH share price forecasts range from $30.00 to $30.00. On average, they expect the company's stock price to reach $30.00 in the next twelve months. This suggests a possible upside of 303.2% from the stock's current price.
View analysts price targets for BLPH or view top-rated stocks among Wall Street analysts.

Bellerophon Therapeutics' stock was trading at $0.90 at the beginning of 2023. Since then, BLPH shares have increased by 726.7% and is now trading at $7.44.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our BLPH earnings forecast.

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) issued its earnings results on Friday, March, 31st. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.05.

Shares of Bellerophon Therapeutics reverse split on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2020. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Pfizer (PFE), Verastem (VSTM), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX) and Dynavax Technologies (DVAX).

(BLPH) raised $60 million in an initial public offering on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

Bellerophon Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (8.90%), Renaissance Technologies LLC (1.63%), BlackRock Inc. (0.92%), Geode Capital Management LLC (0.92%), State Street Corp (0.29%) and Dimensional Fund Advisors LP (0.13%). Insiders that own company stock include Bobae Kim, Life Science Opportu Puissance, New Mountain Investments Ii, L and Wassim Fares.
View institutional ownership trends.

Shares of BLPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BLPH stock can currently be purchased for approximately $7.44.

Bellerophon Therapeutics (NASDAQ:BLPH) has a market capitalization of $77.75 million. The biotechnology company earns $-19,830,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis.

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The official website for the company is www.bellerophon.com. The biotechnology company can be reached via phone at (908) 574-4770 or via email at btinvestorrelations@bellerophon.com.